Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2020

01-06-2020 | Laser | Retinal Disorders

Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines

Authors: Renu P. Rajan, Piyush Kohli, Naresh Babu, C. Dakshayini, Manish Tandon, Kim Ramasamy

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2020

Login to get access

Abstract

Aim

To evaluate the incidence and clinical indications for which eyes were treated for retinopathy of prematurity (ROP) outside the guidelines set by International Classification of ROP (ICROP).

Methods

Medical records of the patients treated at a single tertiary care ophthalmology hospital for ROP from January 2016 to December 2019 were retrospectively analysed to evaluate the indications for which they were treated.

Results

Out of 241 eyes, 33 eyes (13.7%) were treated outside the guidelines. The reasons for the treatment outside the guidelines were structural changes (n = 24, 72.7%), persistent stage 3 ROP that did not show any sign of regression for 6 weeks (n = 7, 21.2%) and active ROP with fellow eye being treated (n = 2, 6.1%). The recorded specific structural changes were tangential traction with temporal vessel straightening concerning for macular distortion and ectopia (n = 5, 15.2%), and stage 3 neovascularisation or ridge with anteroposterior traction with risk of progression to stage 4 disease (n = 19, 57.6%). Pre-plus disease was present in 11 eyes (33.3%).After the treatment, ROP stages regressed and retinal vessels grew either until the ora or at least into zone III in all the treated eyes. None of the eyes showed worsening of structural changes after treatment. The mean follow-up of the patients was 12.4 ± 11.7 months.

Conclusion

Experts occasionally recommend treatment in eyes with disease milder than type 1 ROP. This study may help paediatric retinal practitioners in decision-making in borderline cases.
Literature
1.
Kim SJ, Port AD, Swan R et al (2018) Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol 63(5):618–637PubMedPubMedCentral
2.
Stenkuller PG, Du L, Gilbert C et al (1999) Childhood blindness. J AAPOS 3(1):26–32
3.
Shah PK, Prabhu V, Karandikar SS et al (2016) Retinopathy of prematurity: past, present and future. World J Clin Pediatr 5(1):35–46PubMedPubMedCentral
4.
International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123(7):991–999
5.
Early treatment for retinopathy of prematurity cooperative group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684–1694
6.
Gupta MP, Chan RVP, Anzures R et al (2016) Practice patterns in retinopathy of prematurity treatment for disease milder than recommended by guidelines. Am J Ophthalmol 163:1–10PubMed
7.
Darlow BA, Lui K, Kusuda S et al (2017) International variations and trends in the treatment for retinopathy of prematurity. Br J Ophthalmol 101(10):1399–1404PubMed
8.
Liu T, Tomlinson LA, Ying GS et al (2019) Treatment of non-type 1 retinopathy of prematurity in the postnatal growth and retinopathy of prematurity (G-ROP) study. J AAPOS 23(6):332.e1–332.e6
9.
Moshfeghi DM (2018) Top five legal pitfalls in retinopathy of prematurity. Curr Opin Ophthalmol 29(3):206–209PubMed
10.
Bettman JW (1985) The retinopathy of prematurity: medicolegal aspects. Surv Ophthalmol 29(5):371–373PubMed
11.
Demorest BH (1996) Retinopathy of prematurity requires diligent follow-up care. Surv Ophthalmol 41(2):175–178PubMed
12.
Day S, Menke AM, Abbott RL (2009) Retinopathy of prematurity malpractice claims: the ophthalmic mutual insurance company experience. Arch Ophthalmol 127(6):794–798PubMed
13.
Mills MD (2009) Retinopathy of prematurity malpractice claims. Arch Ophthalmol 127(6):803–804PubMed
14.
Reynolds JD (2007) Malpractice and the quality of care in retinopathy of prematurity (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 105:461–480PubMedPubMedCentral
15.
Wiggins RE Jr, Gold RS, Menke AM (2015) Twenty-five years of professional liability in pediatric ophthalmology and strabismus: the OMIC experience. J AAPOS 19(6):535–540PubMed
16.
Engelhard SB, Collins M, Shah C et al (2016) Malpractice litigation in pediatric ophthalmology. JAMA Ophthalmol 134(11):1230–1235PubMed
17.
Vinekar A, Jayadev C, Dogra MR, Shetty B (2016) Improving follow-up of infants during retinopathy of prematurity screening in rural areas. Indian Paediatr 53:S151–S154
18.
Vinekar A, Avadhani K, Dogra M et al (2012) A novel, low-cost method of enrolling infants at risk for retinopathy of prematurity in centers with no screening program: the REDROP study. Ophthalmic Epidemiol 19(5):317–321PubMed
19.
Adams GG, Bunce C, Xing W et al (2017) Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk. BMJ Open 7(3):e013366PubMedPubMedCentral
20.
Sekeroglu MA, Hekimoglu E, Sekeroglu HT, Arslan U (2013) Retinopathy of prematurity: a nationwide survey to evaluate current practices and preferences of ophthalmologists. Eur J Ophthalmol 23(4):546–552PubMed
21.
Dhawan A, Dogra M, Vinekar A et al (2008) Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 45(6):356–361PubMed
22.
Axer-Siegel R, Maharshak I, Snir M et al (2008) Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 28(6):839–846PubMed
23.
Wu WC, Lien R, Liao PJ et al (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133(4):391–397PubMed
24.
Kong L, Bhatt AR, Demny AB et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56(2):956–961PubMed
25.
Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327–333PubMed
26.
Hong YR, Kim YH, Kim SY et al (2015) Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina. 35(9):1772–1777PubMed
27.
Shukla R, Murthy GVS, Gilbert C et al (2020) Operational guidelines for ROP in India: a summary. Indian J Ophthalmol 68:S108–S114PubMedPubMedCentral
28.
Multicenter trial of cryotherapy for retinopathy of prematurity (1988) Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 106(4):471–479
29.
Multicenter trial of cryotherapy for retinopathy of prematurity (1993) 3 1/2- year outcome-structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 111(3):339–344
30.
Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001) Multicenter trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 119(8):1110–1118
31.
Backeljauw B, Holland SK, Altaye M, Loepke AW (2015) Cognition and brain structure following early childhood surgery with anesthesia. Pediatrics. 136:e1–e2PubMedPubMedCentral
32.
Wang X, Xu Z, Miao C-H (2014) Current clinical evidence on the effect of general anesthesia on neurodevelopment in children: an updated systematic review with meta-regression. PLoS One 9:e85760PubMedPubMedCentral
33.
Quinn GE, Dobson V, Biglan A et al (1995) Correlation of retinopathy of prematurity in fellow eyes in the cryotherapy for retinopathy of prematurity study. Arch Ophthalmol 113(4):469–473PubMed
34.
Fielder AR, Shaw DE, Robinson J, Ng YK (1992) Natural history of retinopathy of prematurity: a prospective study. Eye. 6(3):233–242PubMed
35.
Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group (2004) Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233–248 discussion 248-50PubMedPubMedCentral
36.
Ying GS, Pan W, Quinn GE et al (2017) Inter eye agreement of retinopathy of prematurity from image evaluation in the Telemedicine Approaches to Evaluating of Acute-Phase ROP (e-ROP) study. Ophthalmol Retina 1:347–354PubMedPubMedCentral
37.
Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327–1333PubMed
38.
Roohipoor R, Karkhaneh R, Riazi-Esfahani M et al (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retina 2(9):942–948PubMed
39.
Anilkumar SE, Anandi V, Shah PK et al (2019) Refractive, sensory, and biometric outcome among retinopathy of prematurity children with a history of laser therapy: a retrospective review from a tertiary care center in South India. Indian J Ophthalmol 67(6):871–876PubMedPubMedCentral
40.
Bal S, Ying GS, Tomlinson L, Binenbaum G (2019) Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study Group. Association of weight gain acceleration with risk of retinopathy of prematurity. JAMA Ophthalmol 137(11):1301–1305
Metadata
Title
Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines
Authors
Renu P. Rajan
Piyush Kohli
Naresh Babu
C. Dakshayini
Manish Tandon
Kim Ramasamy
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Keyword
Laser
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-04706-8

Other articles of this Issue 6/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2020 Go to the issue

Letter to the Editor

Communicating with patients with nAMD and their families during the COVID-19 pandemic

Medical Ophthalmology

One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy

Letter to the Editor (by invitation)

Reply to ocular manifestation, eye protection, and COVID-19

Retinal Disorders

The association of polypoidal choroidal vasculopathy clinical phenotypes with previously reported genetic markers

Glaucoma

Quantitative analysis of radial peripapillary capillary plexuses in patients with clinically unilateral pseudoexfoliation syndrome

Glaucoma

Diagnostic power of scleral spur length in primary open-angle glaucoma